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Introduction
Initially introduced to the market in January 1990, fluconazole (FLU) is extensively used, especially as a 150 mg single dose for treatment of vaginal candidiasis. Guidelines published by the Infectious Diseases Society of America (IDSA) suggest FLU treatment for a wide variety of fungal infections. In candidiasis and cryptococcal disease, FLU is often listed as a primary therapy option. Fluconazole is efficacious for the treatment of a wide range of candidal infections including nonneutropenic candidemia, suspected candidiasis in urinary tract infections, and pulmonary cryptococcosis. 2, 3 Fluconazole exhibits excellent cerebrospinal fluid penetration, with concentrations exceeding 70% of serum values in dosages from 50 to 400 mg/day. 4 As a result, FLU also has a prominent place in the treatment of numerous types of fungal central nervous system infections such as meningitis, often as a step down therapy after initial treatment with amphotericin B (AmB). 2, 3 Guidelines for antifungal therapy for blastomycosis, coccidioidomycosis, and histoplasmosis also list FLU as a primary, adjunct, or secondary treatment option. [5] [6] [7] Though FLU has been suspected of being a teratogen since as early as 1992, it is still frequently used during pregnancy. Depression of the T-cell mediated immune response, high estrogen levels, reduced vaginal pH, and increased vaginal glycogen concentrations place pregnant women at an increased risk of vaginal candidiasis, which is easily treated with FLU. 8, 9 Additionally, the risk of dissemination of disease and mortality from coccidioidomycosis and coccidioidal meningitis is significantly higher in pregnant women. 10 Despite its popularity, FLU is thought to cross the placenta and achieve detectable or even therapeutic concentrations in amniotic fluid as well as fetal tissue and cord blood. This property of FLU led to the preference of AmB deoxycholate or lipid formulations of AmB by most published guidelines for susceptible fungal infections in pregnancy. The guideline preference for AmB is specifically directed toward pregnant females in the first trimester, which is the most critical period for development of embryonic and fetal malformations. 9 In August 2011, the U.S. Food and Drug Administration (FDA) issued a safety announcement concerning the use of FLU in pregnancy. On the basis of several published case reports in humans [11] [12] [13] [14] , and animals showing similar causative effects 15 , the FDA changed the pregnancy category of FLU from category C to category D for all indications except FLU 150 mg as a single dose for treatment of vaginal candidiasis, citing trends of "a rare and distinct set of birth defects in infants whose mothers were treated with the drug during the first trimester of pregnancy".included a short, broad head, abnormal looking face, abnormal development of the skullcap, oral cleft, bowing of the thigh bones, thin ribs and long bones, muscle weakness and joint deformities, and congenital heart disease. 16 Created in 1980, the FDA's drug-associated pregnancy risk categories, which consist of the letter designations of A, B, C, D, or X, are assigned according to the known or potential fetal harm associated with drug therapy. Category A represents the least proven harm, while category X represents definitive fetal harm that outweighs any benefit of use in pregnant women. The change from category C to category D for most indications of FLU reflected what the FDA believed to be positive evidence of fetal risk in human studies, rather than evidence of risk from only animal studies. 16 In August 2013, the New England Journal of Medicine published a registry-based historical cohort study by Mølgaard-Nielsen et al. which assessed congenital malformations outcomes after exposure to FLU during the first trimester of pregnancy. 17 The goal of this article is to conduct a comprehensive literature review that incorporates this most recent data with the other published literature regarding the safety of FLU in pregnancy, with the outcome of teratogenicity as a specific focus. ", "Fluconazole", "abnormalities", "pregnancy", "birth", "congenital", "malformations", and "teratogens". For International Pharmaceutical Abstracts, keyword searching and truncated derivations of the keywords were exclusively used. Additional references were identified through a bibliographic search of included references.
Methods
Studies were included for analysis if they were conducted in humans, examined an association between FLU use in pregnancy and congenital malformations as either a primary or secondary endpoint, and were available in English as a fulltext article. Clinical trials, cohorts, case-controls, crosssectionals, case series, case reports, and letters to the editor were all considered for analysis. In total, 14 references ultimately met the criteria for inclusion in this analysis.
Results
The association between FLU use during pregnancy and congenital malformations has been assessed in various types of published literature. These studies are summarized in Table 1 .
Case Reports
Eight individual cases were identified where FLU use during pregnancy was studied in relation to the development of congenital malformations. The earliest of these was presented by Lee et al. in 1992 11 , who reported the case of a premature infant born at 27-weeks to a 22-year-old mother who was treated for disseminated coccidioidomycosis with FLU 400 mg per day from before conception through delivery. The mother was in her second pregnancy, and she had a history of coccidioidal meningitis dating back to her first pregnancy. After treatment with 2600 mg intravenous AmB and 131.5 mg intrathecal AmB, she was placed on FLU and remained on the medication through delivery due to late detection of her pregnancy at 23-weeks gestation. Upon cesarean birth, the infant displayed multiple congenital malformations, including craniosynostosis, contractures of both upper and lower extremities, humeral-radial fusion, bowed tibia and femur, incomplete or shortened digits, and cleft palate. These abnormalities produced a poor prognosis that led to withdrawal of life support and death of the infant. The authors were unable to differentiate their findings from Antley-Bixler syndrome, but suggested possible causation due to similar abnormalities in animal studies with FLU.
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The same 22-year old mother described by Lee et al. 11 had two subsequent pregnancies that were reported by Pursley et al. 12 in 1996. During her third pregnancy, the patient was nonadherent to therapy, delivered a healthy boy, and resumed FLU therapy. She then remained on a regimen of FLU 400 mg/day for coccidioidal meningitis when she was yet again discovered to be 4-months pregnant (gravida 4), upon which FLU therapy was discontinued. The female baby, born at full term, was found to have multiple craniofacial malformations (cleft palate, tracheomalacia, low ears, rudimentary epiglottis, and proptosis), multiple cardiac defects (ventricular septal defect and pulmonary artery hypoplasia), and multiple skeletal malformation (bowed femurs, clavicular fracture, thin and wavy ribs, absent distal phalanx, and arachnodactyly). The infant died at 3 months of age from pneumonia, presumably secondary to tracheomalacia. 12 Pursley et al. 12 also reported the case of a 25-year old mother treated for coccidioidal meningitis with FLU 800 mg/day through delivery at 38 weeks gestation (with a FLU hiatus during weeks 7-9). Congenital abnormalities found upon examination were as follows: flattened occiput, brachycephaly, trigonocephaly, supraorbital ridge hypoplasia, bitemporal narrowing, open cranial sutures, large anterior fontanel, maxillary hypoplasia, short ear helices, micrognathia, exotropia, bowed femurs, diffuse osteopenia, thin ribs, clavicles, and long bones, long metacarpals and phalanges, hypoplastic facial bones, craniofacial disproportion, slanted orbital roofs, tetralogy of Fallot, patent ductus arteriosus, right and left pulmonary artery hypoplasia, patent foramen ovale, and large ventricular septal defect. 12 In 1996, Wiesinger et al. 18 described the case of a 24-year old female admitted at 16-weeks gestation with Candida sepsis.
After failing an AmB test dose, the patient was placed on intravenous FLU therapy (400 mg/day), which was continued for 16 days, at which time she was converted to oral FLU therapy, which continued for an additional 34 days. At 39-weeks gestation the patient delivered a healthy female baby. 18 Aleck and Bartley 13 reported another case of congenital malformation attributed to FLU exposure in 1997, describing a 27-year old mother treated with 400mg/day FLU for coccidioidal meningitis. Due to clinical deterioration, the patient's dose was increased to 800 mg/day. Approximately 4 weeks after the dose increase, the patient was determined to be pregnant, with an estimated gestation of 9 weeks; at that time FLU therapy was discontinued and AmB initiated. Due to further clinical deterioration, at approximately 22-weeks gestation, FLU therapy was reinstituted (1200 mg/day) and the AmB was discontinued. At 31-weeks gestation, the patient delivered a male infant. The baby was found to have multiple congenital malformations including soft calvarium, widely separated cranial sutures, prominent forehead, mild exorbitism, small hemangioma on the tip of the nose, posteriorly angulated ears with over folded helices, bilateral radiohumeral synostosis, and dysplastic hips. of a 9-month-old male infant born to a mother treated for vaginal candidiasis with FLU 800 mg per day from before conception to the 5th month of gestation and again from the 6th month of gestation to delivery. 
Cohort Studies
Five cohort studies were identified that investigated the association of FLU with various birth defects. The first of these was conducted in 1996 by Mastriacovo et al. 23 , who designed a prospective cohort study of women who contacted one of three Teratology Information Services centers in Italy during pregnancy. The exposure group consisted of 226 women who had been exposed to FLU during the first trimester. The control group consisted of 452 women who had not been exposed to FLU during pregnancy. Of the parameters examined (i.e., induced abortions, miscarriages, stillbirths, congenital anomalies, prematurity, low birth weight, cesarean section, and long hospital stay), Research Database to identify 234 women who had been exposed to FLU during the first trimester of pregnancy. Of those exposures, 92% received a single 150 mg dose of FLU, and the study group was matched by age and general practice with 1,629 women without exposure to FLU or other azole medications during pregnancy. The study found no significant increased risk of malformations for FLU users compared with nonusers, with polydactyly-syndactyly, heart defects, and spina bifida among the abnormalities present. 24 Sørensen et al. 25 identified 121 Danish women who had taken FLU during the first trimester of their pregnancies and had subsequently given birth to either a live or stillborn infant. All pregnancies in North Jutland County from January 1, 1991, to December 31, 1996, were included in the study, a sample representative of 9 percent of the Danish national population during that time. These pregnancies were identified using the Danish Medical Birth Registry (DMBR), which tracks all live and still births in Denmark since January 1, 1973, and stores data collected by midwives and doctors attending deliveries. The DMBR follows infants up until one year of age, so it may be used along with the Danish National Registry of Patients (DNRP) to ascertain birth defect data. 25 Sørensen et al. 25 identified FLU exposure during the first trimester using computerized prescription databases. Though the authors were unable to determine daily medication regimens or cumulative doses of FLU received, they assumed that most subjects were given a single 150 mg FLU tablet based on patterns and standards of vaginal candidiasis treatment in Denmark at the time. . None of the malformations were duplicative, with congenital hip dislocation, lacrimal stenosis, partial syndactyly, and ventricular septum deficiencies each appearing in one infant. However, the study was not powered to detect more than a 1.8-fold increased risk of malformations, and the study design did not include spontaneous abortions or abortions performed due to prenatal diagnoses of malformation. 25 Nørgaard et al. 26 published a 2008 study that expanded on the work of Sørensen et al. 25 , using the DMBR to identify women from four Danish counties who gave birth to either live or stillborn infants after the 20th week of gestation. The study encompassed 31 percent of the country's population, and depending on the county, set a date range from either 1991, 1996, or 1998, through 2005. Fluconazole exposure during the first trimester was identified using computerized prescription databases, and all women in the study group (N=1,079) received a "short-course," or 1 to 4 days, of FLU therapy with cumulative exposures of either 150mg (74%), 300mg (22%), 350mg (2%), or 600mg (2%). Exclusions listed in the study were congenital hip dislocation, undescended testes, and known chromosomal aberrations such as Down's syndrome. The crude prevalence odds ratio (POR) for the study group compared to pregnancies not exposed to FLU (N=170,453) was found to be nonsignificant [1.1 (95% CI, 0.8-1.5)], as was a POR adjusted for maternal smoking status, parity, maternal age, and prescriptions for antiepileptics and maternal diabetes [1.0 (95% CI, 0.8-1.4)]. No significant associations or definitive trends were found when congenital abnormalities were analyzed individually, though some malformations occurred multiple times within the study group, including cardiovascular, craniofacial, and musculoskeletal abnormalities, along with club foot and neural tube defects. . A subanalysis that included terminated pregnancies found a significant association between exposure to FLU and hypoplastic left heart [adjusted POR = 2.82 (95% CI, 1.23-6.45)] when "proportion of terminated pregnancies was assumed to be doubled among the exposed pregnancies".
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Discussion
The results of the primary literature document that FLU has been implicated in causing congenital malformations, especially when administered in high doses over a prolonged duration of therapy.
A comprehensive literature review of the literature identified fourteen citations evaluating or discussing FLU use in pregnancy and congenital malformations. Six citations (four case reports, one case series comprised of two cases, and one cross-sectional study) associated FLU exposure during pregnancy with congenital malformations. Seven citations (three registry based cohort studies, one prospective cohort study, one case report, two letters to the editor) found no association between FLU exposure and birth defects. One citation (a registry-based cohort study) found no association between oral FLU exposure during the first trimester of pregnancy and major birth defects as a composite measure, but when examining individual birth defects the investigators did find an increased incidence of tetralogy of Fallot. Those citations linking FLU exposure with congenital malformations implicated its use in the development of craniofacial, skeletal, cardiac, and genitourinary malformations, among others.
A number of references 11, 14, 19 noted similarities between the malformations associated with FLU teratogenicity and those associated with Antley-Bixler syndrome, an autosomal recessive disorder of poorly understood etiology. AntleyBixler syndrome has been associated with mutations in cytochrome P450 oxidoreductase 27, 28 and CYP51 (lanosterol-14 demethylase) 29,30 among other mutations. As reported by Lee et al.
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, the phenotype characteristics associated with Antley-Bixler syndrome include craniofacial malformations such as brachycephaly, craniosynostosis, and midfacial hypoplasia; skeletal malformations such as radiohumeral synostosis, femoral bowing/fractures, thin ribs, arachnodactyly, syndactyly; and genitourinary malformations such as vaginal atresia and renal abnormalities, in addition to other malformation such as hydrocephalus, atrial septal defects, preauricular tags, and hemangioma. 11 The possible teratogenic effects of FLU appear to be highly dependent upon the dose, duration of exposure, and timing of exposure relative to conception. The paucity of significant findings among the five cohort studies can most likely be attributed to the dose and duration of FLU, since the total FLU exposure in these studies rarely exceeded 300 mg. In contrast, the case reports and case series reporting negative FLU effects consisted of prolonged exposure (several months in duration) to high doses (400-1200 mg/day). There was only one case report of congenital malformations after a single 150 mg dose of FLU 19 , promulgating theories on whether other confounding variables could have been contributory to the negative outcome.
In conclusion, there appears to be little to no fetal risk resulting from a single dose or short duration antifungal therapy with FLU; however, prolonged high-dose FLU therapy, such as that required for the treatment of coccidioidal meningitis, has potential for teratogenic effects and the risk of therapy must be weighed against the benefits. 
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